Vaccine, yellow fever

Generic Medicine Info
Indications and Dosage
Active immunisation against yellow fever
Adult: Primary immunisation: 0.5 mL as single dose, at least 10 days prior to travel. Booster dose: Repeat dose every 10 years for those at continued risk of exposure.
Child: ≥9 months Same as adult dose.
Reconstitute with the diluent provided. Inject diluent slowly into vial and allow to stand for 1-2 minutes. Gently swirl until a uniform suspension forms. Avoid vigorous shaking. Use vaccine within 60 minutes of reconstitution. Keep suspension refrigerated until used.
Hypersensitivity to yellow fever vaccine, egg or chicken proteins. Severely immunosuppressed patients (e.g. HIV infection, AIDS, leukaemia, lymphoma, thymic disease, generalised malignancy, or immunosuppression due to drugs or radiation), moderate or moderate or severe febrile illness. Children <9 months. Lactation.
Special Precautions
Patient with acute illness, altered immunocompetence (e.g. asymptomatic HIV infection), bleeding disorders, malnutrition. Children and children born to HIV positive mothers. Pregnancy.
Adverse Reactions
Significant: Syncope, Guillain-Barre syndrome, cranial nerve palsy, acute disseminated encephalomyelitis.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Vomiting, nausea, abdominal pain, diarrhoea.
General disorders and admin site conditions: Malaise, local injection site reactions (e.g. erythema, oedema, pain), fever, irritability.
Metabolism and nutrition disorders: Loss of appetite.
Musculoskeletal and connective tissue disorders: Myalgia, weakness, arthralgia.
Nervous system disorders: Headache, asthenia, drowsiness, dizziness, paraesthesia.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis), vaccine-associated neurotropic disease, vaccine-associated viscerotropic disease.
Monitoring Parameters
Monitor for anaphylaxis and syncope for 15 minutes following administration. Maintain supine or Trendelenburg position to establish adequate cerebral perfusion if seizure-like activity associated with syncope occurs.
Drug Interactions
Decreased immunological response with immunosuppressants (e.g. corticosteroids, antineoplastic).
Lab Interference
False positive result with laboratory diagnostic tests for other flavivirus related disease (e.g. dengue, Japanese encephalitis). May diminish diagnostic effect of tuberculin tests.
Mechanism of Action: Yellow fever vaccine is live attenuated yellow fever virus that induces immunity to yellow fever infection by inducing specific antibody production.
Onset: Seroconversion: 10-14 days.
Duration: ≥30 years.
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed in accordance with local requirements.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BL - Yellow fever vaccines ; Used for active immunizations.
Anon. Yellow Fever Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 10/07/2018.

Anon. Yellow Fever Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 10/07/2018.

Buckingham R (ed). Yellow Fever Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 10/07/2018.

Joint Formulary Committee. Yellow Fever Vaccine, Live. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 10/07/2018.

Stamaril Kit (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 10/07/2018.

YF-Vax Injection, Powder, Lyophilized, for Suspension Sodium chloride Injection (Sanofi Pasteur Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 10/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, yellow fever from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in